In-use in vitro performance of formoterol fumarate dihydrate powder for inhalation (6 and 12 µg/dose) delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Development of formoterol fumarate dihydrate powder for inhalation (6 µg and 12 µg per dose) delivered through a multi dose dry powder inhaler (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003
Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI) Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004
Inhalation parameters from an integrated electronic multidose dry powder inhaler (eMDPI) Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004
Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Flow-dependent performance of several formoterol dry powder inhalers (DPIs) Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006
Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Performance characteristics of a multi dose dry powder inhaler (MDPI) with respect to the use of different deaggregation systems Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Development of a powder for inhalation with R,R-Glycopyrrolate as active ingredient for the delivery from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 471s Year: 2003
Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study. Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020
Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004